Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cevostamab + Dexamethasone + Pomalidomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cevostamab | RO7187797|BFCR4350A | CD3 Antibody 125 | Cevostamab (BFCR4350A) is a bispecific antibody that targets both FCRH5 and CD3, potentially resulting in increased anti-tumor immune response and tumor cell killing (Blood (2020) 136 (Supplement 1): 42-43). | |
| Dexamethasone | Adexone | Desametasone | ||
| Pomalidomide | Pomalyst | CC-4047 | Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07555938 | Phase III | Dexamethasone Daratumumab Elotuzumab Carfilzomib Pomalidomide Cevostamab + Dexamethasone + Pomalidomide | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma (CEVOLUTION) | Recruiting | USA | 1 |